SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR

15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November, 2014

 

Prana Biotechnology Limited

(Name of Registrant)

 

Level 2, 369 Royal Parade Parkville  Victoria  3052 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                   Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):__

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨                      No x 

 

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

 

 
 

 

PRANA BIOTECHNOLOGY LIMITED

 

 

6-K Items

 

1. RESULTS OF ANNUAL GENERAL MEETING

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  PRANA BIOTECHNOLOGY LIMITED
    (Registrant)
     
     
  By: /s/ Geoffrey Kempler  
    Geoffrey Kempler,
    Executive Chairman

  

November 13, 2014

 

 
 

 

 

 

COMPANY ANNOUNCEMENT

(ASX: PBT)

 

RESULTS OF ANNUAL GENERAL MEETING

 

Thursday, 13th November 2014

 

The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a show of hands.

 

In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the proxy votes received for each resolution considered by Members of the Company at the Annual General Meeting held today at 11.30am.

 

  Resolutions For Against Abstain Proxy's Discretion* Total Valid Proxies Received For Percentage
1 Adoption of Remuneration Report ** 48,789,215 5,064,558 3,925,824 5,497,540 63,277,137 91.47%
2a

Election of Director

- Professor Ira Shoulson

 54,808,276 1,696,829 1,497,400 24,052,311 82,054,816 97.89%
2b

Re-election of Director

- Mr Peter Marks

 51,212,435 5,214,770 1,618,411 24,009,200 82,054,816 93.52%
2c

Re-election of Director

- Mr Lawrence Gozlan

 51,144,355 5,299,850 1,558,300 24,052,311 82,054,816 93.42%
3 Ratification of previously issued securities - ATM 51,144,355 5,299,850 1,558,300 24,052,311 82,054,816 93.42%

 

* The Chairman voted undirected proxies in his control in favour of all resolutions.

** Note: Resolution 1 is a special resolution and required 75% approval to be passed. This threshold has been achieved and the resolution has passed.

 

 

On behalf of the Board

 

Phillip Hains

Company Secretary

Prana Biotechnology Limited

 

 

 

Suite 1, 1233 High Street Armadale
Victoria Australia 3143		 Page 1 of 1 Telephone: 61 3 9824 5254
Facsimile: 61 3 9822 7735